Federal Rescheduling Update: A Targeted Shift and What It Means for the Cannabis Industry

Executive Summary

On April 23, 2026, the U.S. Department of Justice issued a final order placing FDA-approved marijuana products and marijuana products used within state-licensed medical frameworks into Schedule III of the Controlled Substances Act.

This marks the first time in over 50 years that any category of marijuana has been formally reclassified at the federal level.

However, this action does not represent full rescheduling. Cannabis remains a Schedule I substance in all other contexts, including adult-use markets. A broader determination is still pending, with the Drug Enforcement Administration (DEA) scheduled to begin administrative hearings on June 29, 2026.

For investors and operators, the takeaway is clear: federal policy is advancing, but unevenly. The industry is now operating within a transitional framework that combines elements of both Schedule I and Schedule III treatment.

Current Status of Rescheduling

The April 23 DOJ order establishes a limited and targeted reclassification, rather than a comprehensive policy shift.

Under the order:

• FDA-approved marijuana-based drug products are placed in Schedule III
• Certain marijuana activities conducted under qualifying state medical programs are also moved into Schedule III

At the same time:

• Adult-use cannabis remains Schedule I
• Unlicensed or non-compliant activity remains Schedule I

This creates a segmented regulatory environment, where federal treatment varies depending on product type, use case, and compliance structure.

Importantly, this action exists alongside the broader rescheduling process initiated following the Department of Health and Human Services’ recommendation. That broader process is still ongoing.

Key Dates in April

Federal activity between mid-April and late April 2026 accelerated meaningfully.

April 23, 2026 – DOJ Final Order
The Department of Justice issued a final order placing specific marijuana categories into Schedule III, marking a historic shift in federal drug policy.

April 28, 2026 – DEA Hearing Confirmation
The DEA confirmed the start of an administrative hearing on June 29, 2026, to evaluate broader rescheduling of marijuana under the Controlled Substances Act.

April 29, 2026 – DEA Registration Portal Opens
The DEA launched a new registration portal through its Diversion Control Division, allowing certain participants in the medical marijuana ecosystem to apply for federal registration.

While historically limited to researchers and manufacturers, the expansion of this system signals increased federal infrastructure development in anticipation of potential policy changes.

Together, these steps reflect a coordinated federal effort, not a full policy resolution, but a transition from review into phased implementation.

What the DOJ Order Changes

The April 23 order introduces several meaningful developments:

Federal Recognition of Medical Use

By placing defined categories of marijuana into Schedule III, the federal government formally acknowledges accepted medical use for those categories.

Potential Tax Implications

Schedule III substances are not subject to Section 280E of the Internal Revenue Code. If applied in practice, this could improve financial conditions for qualifying entities. However, the scope and implementation of 280E relief remain subject to further guidance.

Expanded Federal Engagement

The introduction of DEA registration pathways signals a shift toward more formal federal oversight and participation in cannabis-related activity.

What Has Not Changed

Despite the significance of the April 23 order, key aspects of federal cannabis policy remain unchanged.

Adult-Use Cannabis Status

Recreational cannabis remains a Schedule I substance pending the outcome of the DEA’s upcoming administrative process.

Interstate Commerce

The order does not authorize interstate transport of cannabis.

Banking and Capital Access

No direct changes have been made to federal banking restrictions.

Full Federal Legalization

Cannabis remains a controlled substance. This is a reclassification of certain categories, not a removal from the Controlled Substances Act.

Strategic Implications for Investors and Operators

The current environment introduces both opportunity and complexity.

A Segmented Regulatory Landscape

Federal policy is no longer uniform. Operators must navigate a system where different categories of cannabis may be treated differently under federal law.

Compliance as a Competitive Advantage

As federal engagement increases, alignment with both state and emerging federal standards becomes more important. Businesses that are already structured with strong compliance frameworks will be better positioned.

Financial Planning Remains Conditional

While potential 280E relief represents a significant upside, uncertainty around scope and timing means that projections should remain conservative.

Infrastructure Before Expansion

The federal government appears to be building regulatory infrastructure ahead of broader policy changes. This suggests a phased approach rather than an immediate market transformation.

What to Watch Next

Key developments to monitor include:

June 29, 2026: DEA administrative hearing on broader rescheduling

• outcomes of the hearing and any subsequent rulemaking
• clarification from the IRS regarding 280E applicability
• participation and scope of the DEA registration program
• alignment (or divergence) across federal agencies

These factors will shape how. and how quickly, federal policy continues to evolve.

The Bottom Line

The April 23 DOJ order represents a historic shift, introducing Schedule III treatment for defined categories of marijuana while leaving the broader market unchanged. This creates a transitional environment where policy is advancing in targeted ways rather than through a single, comprehensive reform.

For investors and operators, the focus should remain on disciplined execution within existing frameworks while closely monitoring federal developments.

In a regulated industry, clarity rarely arrives all at once. It is built through stages, and this is one of them.

About Cannabis Business Advisors

For operators, investors, and entrepreneurs navigating cannabis policy and emerging markets, understanding how regulatory developments translate into operational strategy is critical.

Cannabis Business Advisors (CBA) tracks legislative developments, regulatory changes, and market dynamics across the United States to help industry leaders make informed decisions in a rapidly evolving industry. If you are evaluating opportunities in the cannabis market or want to discuss how recent regulatory shifts could impact market entry and compliance strategy overall, contact us at 602-290-9424 for additional insights.

This article is part of CBA’s ongoing state policy intelligence series tracking regulatory developments across emerging cannabis markets.

 

The Cannabis Business Advisors have more than thirty years of combined industry experience, spanning across the U.S. and around the globe. C.B. Advisors offers a comprehensive suite of services, including application and licensing preparation, operational analysis, merger and acquisition support, policy and procedures, exit strategy guidance, and business development planning. Stay up to date on the latest cannabis news with The CB Advisors!

Contact Info@thecannabisbusinessadvisors.com for more information on how to apply for a cannabis business license.